For example, UK SmPCs for GLP-1 receptor agonists advise caution in patients with a history of pancreatitis or gallbladder disease, and include precautionary guidance regarding thyroid symptoms (such as a neck mass, difficulty swallowing, or hoarseness) that should be reported promptly
[1] [3] This 21-day window applies to pens that remain in their original packaging
/ /
Individual results vary based on genetics, compliance, diet, and exercise habits
It still remains to be seen as to what the incoming administration will do. The Trump administration will also face another decision on GLP-1 medications with the HHS recent proposal that Medicare and Medicaid cover anti-obesity medications
Makris MC, Alexandrou A, Papatsoutsos EG, et al